BETMIGA

the actual benefit of BETMIGA is low in the symptomatic treatment of urgency and increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder syndrome.

This actual benefit is provisional pending the results of the study versus VESICARE.

BETMIGA does not procure an improvement in actual benefit (LAB level V, non-existent) in the symptomatic treatment of urgency and increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder syndrome and, in particular, pending the results of the study versus VESICARE.